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Abstract
Background This study aimed to investigate whether schedule modification is safe and effective in patients intolerant to the 
standard eribulin dose and schedule.
Methods Patients with metastatic breast cancer (MBC) treated with both anthracycline and taxane and ≤ 3 prior regimens 
of chemotherapy for MBC received eribulin at the standard dose and schedule (1.4 mg/m2 on days 1 and 8 of a 21-day cycle) 
in the first cycle; change of dosing schedule (1.4 mg/m2 on days 1 and 15 of a 28-day cycle) was determined by change in 
neutrophil count, platelet count, aspartate aminotransferase, alanine aminotransferase, total bilirubin, serum creatinine, 
and non-hematological toxicity on day 8 of the first cycle or day 1 of the second cycle. Clinical benefit rate (CBR; primary 
endpoint), time to treatment failure (TTF), overall survival (OS), and safety were evaluated.
Results Of the 88 patients who were enrolled and received standard eribulin therapy in the first cycle, 42 patients were 
moved to the bi-weekly therapy group and 40 continued standard therapy. In the bi-weekly and standard therapy groups, 
mean relative dose intensity was 62.7 and 90.9%, CBR was 31.0 and 25.0%, median TTF was 81.5 and 75 days, and OS was 
523 and 412 days, respectively. Neither group reported severe adverse events.
Conclusion This is the first study to show that a bi-weekly eribulin schedule is tolerable and has comparable efficacy in 
patients intolerant to the standard eribulin schedule.
Clinical trial registration University Hospital Medical Information Network (UMIN) Center (ID: UMIN 000008491).
Keywords Eribulin · Schedule modification · Metastatic breast cancer · Bi-weekly schedule
Introduction
Microtubule polymerization is a key process in cancer 
cell proliferation and a number of microtubule-targeting 
agents have been evaluated in preclinical and clinical stud-
ies [1]. Eribulin, an analog of halichondrin B, is a novel 
non-taxane microtubule dynamics inhibitor [2]. Because 
eribulin binds to a unique site on tubulin [3], it can be used 
to overcome taxane resistance and can be used in patients 
progressing after standard treatment with anthracycline- 
and taxane-containing regimens [4]. It has been approved 
in many countries for the treatment of metastatic breast 
cancer (MBC) in patients previously treated with chemo-
therapeutic agents like anthracycline- and taxane-based 
regimens [5–7]. In Japan, it is approved for the treatment 
of patients with inoperable or recurrent breast cancer [8] 
and is being investigated in patients who have not been pre-
viously treated with chemotherapy regimens for MBC [9].
Several clinical trials have demonstrated the antitumor 
activity and tolerability of eribulin. A global, multicenter, 
open-label, phase III, randomized study (EMBRACE 
study) demonstrated a significant and clinically meaning-
ful improvement in overall survival (OS) with eribulin 
compared to that with treatment of physician’s choice in 
patients with heavily pre-treated MBC (median OS 13.1 
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vs. 10.6 months, p = 0.041) [10]. In another randomized 
phase III study (301 study), median OS in the eribulin 
group was longer than that in the capecitabine group, 
though the results were not significantly different [15.9 vs. 
14.5 months, hazard ratio (HR) 0.88; 95% confidence inter-
val (CI) 0.77–1.00; p = 0.056] [11]. A pooled analysis of 
these two phase III studies demonstrated that eribulin sig-
nificantly improved OS compared to control in various sub-
groups of patients with pretreated MBC [12]. A single-arm, 
multicenter, open-label phase II study conducted in Japan, 
which enrolled MBC patients pretreated with an anthra-
cycline and a taxane, has also shown both the efficacy and 
tolerability of eribulin as first- to fourth-line treatment [13].
Although eribulin demonstrated a manageable safety 
profile, the incidence of myelosuppression is high. In the 
EMBRACE trial, adverse events occurred in 98.8% patients 
receiving eribulin [10]. The incidence of both neutropenia 
and leukopenia was 98.8% in the Japanese phase II study 
[13]. In the MBC population known to have low quality of 
life (QOL) [14], adverse events may have further unfavora-
ble impact on patient well-being and may lead to discon-
tinuation of the eribulin therapy especially in severe cases. 
A comparison of the clinical benefits of eribulin versus 
capecitabine using health-related QoL (HRQoL) data from 
a phase III randomized trial in patients with MBC showed 
similar impact on patient functioning with no overall dif-
ference in HRQoL; however, patients who received eribulin 
showed worse systemic side-effects of chemotherapy such 
as dry mouth, different tastes, irritated eyes, feeling ill, hot 
flushes, headaches, and hair loss and lesser gastrointestinal 
toxicity compared to those receiving capecitabine [15]. The 
main aims of MBC treatment are prolonging OS and main-
taining QOL. While non-hematologic toxicity is lower with 
eribulin than with other chemotherapeutic agents, discon-
tinuation due to hematologic toxicity is a major problem of 
eribulin therapy. Management of neutropenia is important 
to continue eribulin treatment for clinical benefits. Since the 
standard dosing schedule of eribulin often leads to severe 
neutropenia, the management of eribulin dose and schedule 
is a key issue to decrease toxicity and continue treatment. 
Dose reduction of eribulin has been reported for patients 
with adverse events of higher grades in the previous studies 
[10, 13]. We conducted a phase II, non-randomized, pro-
spective study to investigate whether schedule modification 
of bi-weekly eribulin therapy is safe and effective.
Patients and methods
Patients
Japanese women with MBC previously treated with an 
anthracycline and a taxane, and who had received up to 
three prior regimens of chemotherapy for MBC were 
included in the study. The main inclusion criteria were as 
follows: women aged ≥ 20 years, histologically confirmed 
human epidermal growth factor receptor 2 (HER2)-nega-
tive breast cancer, Eastern Cooperative Oncology Group 
performance status (ECOG PS) [16] of 0–2, measurable 
lesion in at least one dimension by computed tomography 
or magnetic resonance imaging based on Response Evalu-
ation Criteria in Solid Tumors (RECIST) ver. 1.1. [17], 
neutrophil count ≥ 1000/μL, platelet count ≥ 100,000/μL, 
hemoglobin ≥ 9.0 g/dL, aspartate aminotransferase and ala-
nine aminotransferase ≤ 3.0 times the upper limit of normal 
(ULN) or ≤ 5.0 × ULN in patients with hepatic metastases, 
total bilirubin ≤ 1.5 × ULN, serum creatinine ≤ 1.5 × ULN, 
and expected survival of ≥ 3 months.
Key exclusion criteria were as follows: systemic infection 
with fever ≥ 38.0 °C, pleural effusion, ascites or pericar-
dial fluid requiring drainage, symptomatic brain metastasis, 
serious comorbidities (e.g., ischemic heart disease not con-
trollable by treatment or heart disease such as arrhythmia, 
myocardial infarction < 6 months prior to study entry, com-
plication of interstitial pneumonia or pulmonary fibrosis), 
second active cancer, inadequately controlled diabetes mel-
litus, pregnancy, breastfeeding, or women with childbearing 
potential.
Study design
In the first cycle, 1.4 mg/m2 eribulin mesylate (equivalent 
to 1.23 mg/m2 of eribulin as free base) was administered 
intravenously over 2–5 min on days 1 and 8 of each 21-day 
cycle (the standard regimen). Based on the incidence of 
adverse events prior to eribulin administration on day 8 of 
the first cycle or day 1 of the second cycle, patients were 
allocated to standard therapy group or bi-weekly therapy 
group on day 1 of the second cycle. The criteria for dosing 
schedule modification included neutrophil count ≥ 1000/
μL, platelet count ≥ 75,000/μL, aspartate aminotrans-
ferase and alanine aminotransferase ≤ 3.0 times the ULN 
or ≤ 5.0 × ULN in patients with hepatic metastases, total 
bilirubin ≤ 1.5 × ULN, serum creatinine ≤ 1.5 × ULN, 
non-hematological toxicity with grade ≤ 2. When patients 
met these criteria, they continued the standard regimen. 
But otherwise, they were allocated to the bi-weekly ther-
apy, where 1.4 mg/m2 eribulin mesylate (equivalent to 
1.23 mg/m2 of eribulin as free base) was administered on 
days 1 and 15 of each 28-day cycle. Eribulin was admin-
istered until disease progression, unacceptable toxicity, or 
withdrawal of consent. Table S1 shows the dosing sched-
ule for patients switching to bi-weekly eribulin admin-
istration and requiring dose reduction and/or delayed 
administration.
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After patients were allocated to the two groups, they con-
tinued to receive eribulin treatment in the same group. Dose 
reduction to 1.1 mg/m2 was permitted to manage toxicity of 
grade ≥ 3 febrile neutropenia, grade ≥ 3 neutropenia with 
infection requiring antibiotic treatment, grade 4 thrombocy-
topenia, or grade ≥ 3 non-hematological toxicity.
Eribulin administration was discontinued for patients 
requiring dose reduction to < 1.1 mg/m2 or delay in admin-
istration > 2 weeks. Administration of granulocyte colony-
stimulating factor (G-CSF) was permitted in the event of 
grade 4 neutropenia or grade ≥ 3 febrile neutropenia; how-
ever, the use of G-CSF for preventing neutropenia was not 
permitted.
Rationale for dosing schedule modification
Table S2 shows the theoretical dose intensity of eribulin 
in the standard schedule and bi-weekly schedule. When 
patients were unable to continue eribulin treatment on the 
standard regimen (1.4 mg/m2 on days 1 and 8 of each 21-day 
cycle), the dose reduction to 1.1 mg/m2 on the same dos-
ing schedule had been determined in the previous studies 
[10, 11] in which the dose intensity decreased to 0.73 mg/
m2 per week. A similar (0.70 mg/m2) dose intensity was 
maintained in bi-weekly schedule with the dose of 1.4 mg/
m2 in this study.
Assessments
The primary endpoint of this study was clinical benefit rate 
(CBR, defined as the proportion of patients who achieved 
complete response, partial response, or stable disease 
for ≥ 6 months) based on RECIST v. 1.1. Secondary end-
points included time to treatment failure (TTF), OS, and 
safety. TTF was defined as the time from initiation of eribu-
lin to treatment discontinuation for any reason, including 
disease progression, treatment toxicity, patient preference, 
or death caused by treatment. OS was calculated as the time 
from the initiation of eribulin until death from any cause. For 
safety, adverse events were recorded and graded according to 
the National Cancer Institute Common Terminology Criteria 
for Adverse Events (version 4.0, Japanese version) [18], and 
were coded according to Medical Dictionary for Regula-
tory Activities, Japanese version [19]. In addition, ad hoc 
analyses were performed: factors influencing the schedule 
modification of eribulin to bi-weekly administration were 
evaluated, and subgroup analyses were performed in elderly 
(aged ≥ 65 years) and younger (aged < 65 years) patients.
The study protocol was approved by local institutional 
review boards and ethics committees. This study was con-
ducted in accordance with the Japanese Guidelines for Clini-
cal Research of the Ministry of Health, Labour and Welfare 
and the Declaration of Helsinki, as well as other applicable 
regulatory requirements. All participants provided writ-
ten informed consent prior to the study entry. The present 
study has been registered with the University Hospital 
Medical Information Network (UMIN) Center (ID: UMIN 
000008491) [20].
Statistical methods
The sample size was calculated to evaluate the null hypoth-
esis that the true CBR was 15% and the alternative hypoth-
esis that the CBR was ≥ 30%, with a type I error level of 0.1 
and type II error level of 0.20. The minimum target sample 
size was set at N = 70 and we aimed to recruit 80 patients 
with the consideration that ~ 10% of the recruited patients 
would not be evaluable. In the phase II clinical trial of eribu-
lin in Japan, patients had a CBR of 27.5% with a median of 
3 prior chemotherapy sessions. In addition, 33.3% of the 
patients could not be administered eribulin on day 8 of cycle 
1 because of myelosuppression. Based on these findings, we 
assumed that 50% of the patients would not be eligible for 
eribulin on day 8 of cycle 1 in clinical practice.
The data cut-off date was February 25, 2016. The efficacy 
data were assessed in the eligible population who received at 
least one dose of the study drug and had evaluable efficacy 
data (full analysis set; FAS). The CBR and two-sided 95% 
CIs were calculated based on binominal distribution. TTF 
and OS (estimated median with 95% CI) were calculated 
using Kaplan–Meier methods. The safety data were assessed 
in the eligible population who received at least one dose of 
the study drug (safety population), which were presented 
by descriptive analyses. SAS software (version 9.4) (SAS 
Institute Inc., Cary, NC, USA) was used for all analyses.
Results
We conducted a phase II, prospective, non-randomized, 
open-label, multicenter study at 16 sites in Japan. A total of 
88 patients were recruited in the study between July 2012 
and April 2014. All 88 patients received at least one dose 
of eribulin. A total of 82 patients were eligible for efficacy 
analyses (FAS); 40 patients continued the standard eribu-
lin therapy (standard group) and the remaining 42 patients 
required schedule modification (bi-weekly group) (Fig. 1).
The baseline characteristics of patients are summarized in 
Table 1. Although patients in bi-weekly group were intoler-
ant to standard regimens, the characteristics and medical 
history were similar between the two groups.
Eribulin was administered for a median of 73.0 days 
(range 14–365) in the overall population, 77.0 days (range 
35–322) in the standard group, and 87.0 days (range 28–365) 
in the bi-weekly group. Mean relative dose intensity was 
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76.9% in the overall population, 90.9% in the standard 
group, and 62.7% in the bi-weekly group when the dose 
intensity of 0.93 mg/m2/week was considered as 100%.
Efficacy outcomes
The ORR and CBR were 19.3% (95% CI 11.7–29.1) and 
26.1% (95% CI 17.3–36.6) in the overall population, 20.0% 
(95% CI 9.1–35.6) and 25.0% (95% CI 12.7–41.2) in the stand-
ard group, and 21.4% (95% CI 10.3–36.8) and 31.0% (95% 
CI 17.6–47.1) in the bi-weekly group, respectively (Table 2).
The median TTF and OS were 77 days (95% CI 70–95) 
and 427 days (95% CI 300–701) in the overall population, 
75 days (95% CI 69–119) and 412 days (95% CI 275–713) 
in the standard group, and 81.5 days (95% CI 73–107) and 
523 days (95% CI 350–828) in the bi-weekly group (Table 2).
Safety outcomes
In the overall population, the most common adverse events 
with eribulin were leukopenia (83.0%), neutropenia (77.3%), 
anemia (58.0%), fatigue (56.8%), and alopecia (56.8%) 
(Table 3). The most common grade 3 and 4 AEs were neu-
tropenia (59.1%) and leukopenia (45.5%). In the bi-weekly 
group, the incidence rates of leukopenia and neutropenia of 
any grade were 95.2 and 92.9%, respectively, whereas in the 
standard group, the corresponding incidence rates were 72.5 
and 62.5%, respectively. Febrile neutropenia was observed 
in one (2.5%) patient in the standard group and five (11.9%) 
patients in the bi-weekly group (Table 3).
Among patients in the bi-weekly group, grade 3/4 neu-
tropenia was the major adverse event leading to schedule 
modification and reported in 34 patients (81.0%) (Table 4). 
Grade 3/4 leukopenia was reported in 22 patients (52.4%). 
After transition to the bi-weekly schedule, grade 3/4 neutro-
penia reduced to 61.9% and grade 3/4 leukopenia to 26.2%. 
The frequencies of grade 3/4 neutropenia and leukopenia 
during treatment cycles are shown in Fig. 2. By the modifi-
cation of dosing schedule, the frequencies of these toxicities 
were dramatically decreased and the low incidences were 
maintained thereafter. Only 2 (4.8%) patients experienced 
febrile neutropenia after schedule modification. The adverse 
events leading to discontinuation of eribulin were neutrope-
nia (6 patients; 14.3%) and peripheral sensory neuropathy 
(1 patient; 2.4%) in the bi-weekly group (data not shown). 
No patients discontinued the study due to adverse event(s) 
in the standard group.
Ad hoc analyses
In the ad hoc analyses, we determined the association of dos-
ing schedule modification with the baseline characteristics 
Fig. 1  Patient disposition. FAS 
full analysis set
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including age, neutrophil count (Table  5), presence of 
liver metastases, aspartate aminotransferase level, alanine 
aminotransferase level, and blood albumin level (data not 
shown). However, these were not significantly associated 
with the schedule modification of eribulin (Table 5).
In elderly patients (aged ≥ 65 years), the CBR (Table 5) 
and ORR (data not shown) were 35.7 and 21.4% in the 
standard group, and 33.3 and 25.0% in the bi-weekly 
group, respectively. On the other hand, in younger patients 
(aged < 65 years), the CBR and ORR were 19.2 and 19.2% 
in the standard group, and 30.0 and 20.0% in the bi-weekly 
group, respectively. Most likely, elderly patients may be sus-
ceptible to myelosuppression and be unable to continue on 
the standard schedule of eribulin. Bi-weekly eribulin therapy 
is an effective and safe option for elderly patients.
Discussion
Management of eribulin dose and schedule is a key issue 
to decrease toxicity and increase efficacy. Among patients 
who required schedule modification, the majority of patients 
(76.2%) needed it due to neutropenia. Although leukopenia 
and neutropenia were more frequently observed in patients 
who required schedule modification compared with those 
who continued the standard regimen of eribulin, before 
and after switching to bi-weekly administration, incidence 
of grade 3/4 leukopenia decreased from 52.4 to 26.2% and 
grade 3/4 neutropenia decreased from 81.0 to 61.9%. By 
modification of dosing schedule, the frequencies of these 
toxicities were dramatically decreased in the second cycle 
and thereafter. There was no incidence of grade 4 of leuko-
penia and neutropenia after 4 cycles in bi-weekly therapy, 
suggesting that the majority of patients transferred to the 
Table 1  Baseline characteristics of patients
Overall population = safety population = 88 patients
6 patients were excluded (2 due to progressive disease, 2 due to 
adverse events, 1 due to complication, 1 due to refusal)
Standard therapy group = efficacy analysis population = 40 patients
Biweekly therapy group = efficacy analysis population = 42 patients
ECOG Eastern Cooperative Oncology Group, ER estrogen receptor, 
PgR progesterone receptor, FEC 5-FU + epirubicin + cyclophospha-
mide, MBC metastatic breast cancer, S1 tegafur/gimeracil/oteracil 
potassium, XC capecitabine + cyclophosphamide
a Data shown are for > 10% of patients
Overall Standard Bi-weekly
N = 88 N = 40 N = 42
Median age, (range) 
years
59.5 (37–80) 61.0 (37–80) 60.0 (40–77)
ECOG performance status, n (%)
 0 59 (67.0) 26 (65.0) 30 (71.4)
 1 28 (31.8) 14 (35.0) 12 (28.6)
 2 1 (1.1) 0 0
ER/PgR positive, n (%) 54 (61.4) 23 (57.5) 27 (64.3)
Triple-negative, n (%) 34 (38.6) 17 (42.5) 15 (35.7)
No. of chemotherapies for MBC, n (%)
 0 15 (17.0) 5 (12.5) 9 (21.4)
 1 23 (26.1) 14 (35.0) 8 (19.0)
 2 27 (30.7) 10 (25.0) 14 (33.3)
 3 23 (26.1) 11 (27.5) 11 (26.2)
No. of prior chemother-
apy regimens (median)
2 2 2
Prior chemotherapy for  MBCa, n (%)
 FEC 26 (29.5) 10 (25.0) 13 (31.0)
 Paclitaxel + bevaci-
zumab
26 (29.5) 13 (32.5) 10 (23.8)
 nab-Paclitaxel 12 (13.6) 3 (7.5) 8 (19.0)
 Paclitaxel 13 (14.8) 7 (17.5) 6 (14.3)
 S-1 12 (13.6) 4 (10.0) 6 (14.3)
 XC 11 (12.5) 5 (12.5) 6 (14.3)
 Capecitabine 15 (17.0) 9 (22.5) 5 (11.9)
 Docetaxel 6 (6.8) 4 (10.0) 2 (4.8)
Prior surgery, n (%) 79 (89.8) 36 (90.0) 37 (88.1)
Prior radiation therapy, 
n (%)
29 (33.0) 10 (25.0) 15 (35.7)
Most common metastatic  sitesa, n (%)
 Liver 47 (53.4) 21 (52.5) 24 (57.1)
 Bone 41 (46.6) 22 (55.0) 18 (42.9)
 Lymph nodes 24 (27.3) 10 (25.0) 12 (28.6)
 Lung 19 (21.6) 9 (22.5) 7 (16.7)
 Axilla 14 (15.9) 6 (15.0) 7 (16.7)
No. of metastatic sites, 
median
1 1 2




Best overall response, n (%)
 Complete response 2 (2.3) 1 (2.5) 1 (2.4)
 Partial response 15 (17.0) 7 (17.5) 8 (19.0)
 Stable disease 23 (26.1) 9 (22.5) 13 (31.0)
 Stable disease ≥ 6 months 6 (6.8) 2 (5.0) 4 (9.5)
 Progressive disease 37 (42.0) 21 (52.5) 15 (35.7)
 Not evaluable 5 (5.7) 0 1 (2.4)
Objective response rate, n (%) 17 (19.3) 8 (20.0) 9 (21.4)
 95% CI 11.7–29.1 9.1–35.6 10.3–36.8
Clinical benefit rate, n (%) 23 (26.1) 10 (25.0) 13 (31.0)
 95% CI 17.3–36.6 12.7–41.2 17.6–47.1
Time to treatment failure, days 77 75 81.5
 95% CI 70–95 69–119 73–107
Overall survival, days 427 412 523
 95% CI 300–701 275–713 350–828
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bi-weekly regimen could continue eribulin therapy safely for 
8 courses. Furthermore, the frequency of hospital visits was 
20% lower with the bi-weekly schedule as compared with 
the standard schedule.
The efficacy results of patients who required schedule 
modification were comparable to those of patients who con-
tinued the standard eribulin regimen. In addition, our ad 
hoc analyses demonstrated that the tolerability of eribulin 
was comparable between patients aged < 65 years and those 
aged ≥ 65 years. Thus, eribulin may also be beneficial for 
elderly patients.
The efficacy results with the modified bi-weekly schedule 
in the present study were comparable to those of a previous 
phase II study conducted in Japan with the standard regi-
men [13]. CBR and ORR were 31.0 and 21.4% in patients 
who received bi-weekly therapy of eribulin, compared to 
27.5 and 21.3%, in patients on the standard regimen in the 
previous phase II study [13]. The median OS was also simi-
lar and was 523 days (17.2 months) in the present study and 
11.1 months in the previous phase II study [13]. In addi-
tion, the adverse events observed in the present study were 
consistent with those in previous phase II/III studies con-
ducted globally or in Japan [10–13, 21–25], and no new 
safety signals were detected. Hematological toxicities are 
common with eribulin. In the present study, the majority of 
patients experienced hematologic adverse events, including 
neutropenia and leucopenia. In the overall population, grade 
3/4 neutropenia was observed in 59.1%, and grade 3/4 leu-
kopenia was observed in 45.5% of patients, figures which 
are relatively low compared to the previous phase II study 
conducted in Japan (95.1 and 74.1%, respectively) [13]. 
Moreover, the incidence of grade 3/4 febrile neutropenia in 
the present study was 8.0%, which was lower than the 13.6% 
Table 3  Adverse events
ALT alanine aminotransferase, AST aspartate aminotransferase
Overall (N = 88) Standard (N = 40) Bi-weekly (N = 42)
Any grade Grade 3 Grade 4 Any grade Grade 3 Grade 4 Any grade Grade 3 Grade 4
Hematologic events, n (%)
 Leukopenia 73 (83.0) 32 (36.4) 8 (9.1) 29 (72.5) 9 (22.5) 2 (5.0) 40 (95.2) 22 (52.4) 3 (7.1)
 Neutropenia 68 (77.3) 28 (31.8) 24 (27.3) 25 (62.5) 9 (22.5) 3 (7.5) 39 (92.9) 18 (42.9) 19 (45.2)
 Anemia 51 (58.0) 3 (3.4) 0 24 (60.0) 3 (7.5) 0 23 (54.8) 0 0
 Thrombocytopenia 16 (18.2) 3 (3.4) 0 9 (22.5) 2 (5.0) 0 5 (11.9) 0 0
 Febrile neutropenia 7 (8.0) 7 (7.0) 0 1 (2.5) 1 (2.5) 0 5 (11.9) 5 (11.9) 0
Non-hematologic events, n (%)
 AST increased 45 (51.1) 3 (3.4) 0 18 (45.0) 0 0 24 (57.1) 2 (4.8) 0
 Alopecia 50 (56.8) 0 0 26 (65.0) 0 0 23 (54.8) 0 0
 Peripheral sensory neuropathy 42 (47.7) 1 (1.1) 0 18 (45.0) 0 0 22 (52.4) 1 (2.4) 0
 Fatigue 50 (56.8) 5 (5.7) 0 24 (60.0) 4 (10.0) 0 22 (52.4) 1 (2.4) 0
 Malaise 46 (52.3) 0 0 22 (55.0) 0 0 19 (45.2) 0 0
 ALT increased 37 (42.0) 2 (2.3) 0 17 (42.5) 0 0 18 (42.9) 2 (4.8) 0
 Nausea 32 (36.4) 1 (1.1) 0 15 (37.5) 0 0 17 (40.5) 1 (2.4) 0
 Dysgeusia 32 (36.4) 0 0 18 (45.0) 0 0 12 (28.6) 0 0
 Mucositis oral 21 (23.9) 1 (1.1) 0 9 (22.5) 0 0 11 (26.2) 1 (2.4) 0
 Pain 24 (27.3) 3 (3.4) 0 12 (30.0) 0 0 9 (21.4) 2 (4.8) 0
 Constipation 18 (20.5) 0 0 8 (20.0) 0 0 8 (19.0) 0 0
 Peripheral motor neuropathy 14 (15.9) 2 (2.3) 0 4 (10.0) 0 0 8 (19.0) 1 (2.4) 0
 Nail discoloration 11 (12.5) 0 0 5 (12.5) 0 0 6 (14.3) 0 0
 Edema limbs 9 (10.2) 0 0 4 (10.0) 0 0 5 (11.9) 0 0
 Rash maculo-papular 4 (4.5) 1 (1.1) 0 0 0 0 4 (9.5) 1 (2.4) 0
 Vomiting 5 (5.7) 0 0 2 (5.0) 0 0 3 (7.1) 0 0
 Pharyngitis 4 (4.5) 0 0 1 (2.5) 0 0 3 (7.1) 0 0
 Diarrhea 5 (5.7) 0 0 3 (7.5) 0 0 2 (4.8) 0 0
 Blood bilirubin increased 7 (8.0) 0 0 3 (7.5) 0 0 2 (4.8) 0 0
 Nail loss 1 (1.1) 0 0 0 0 0 1 (2.4) 0 0
 Skin hyperpigmentation 3 (3.4) 0 0 2 (5.0) 0 0 1 (2.4) 0 0
 Creatinine increased 9 (10.2) 2 (2.3) 0 7 (17.5) 2 (5.0) 0 1 (2.4) 0 0
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in the previous phase II study [13]. Only 2 (4.8%) patients 
experienced febrile neutropenia after schedule modification.
To our knowledge, this is the first study investigating 
safety and effectiveness of bi-weekly administration of 
eribulin in patients with MBC; however, this study has some 
limitations. This was a non-randomized study: the patients 
were not randomly assigned to the standard group and bi-
weekly group and the patients in the bi-weekly group were 
those who were unable to continue the standard regimen 
of eribulin. Moreover, sample sizes of both groups (stand-
ard schedule and bi-weekly schedule) as well as subgroups 
Table 4  Adverse events: before/
after schedule modification 
(bi-weekly group; N = 42)
ALT alanine aminotransferase, AST aspartate aminotransferase
Adverse events, n (%) Before schedule modification After schedule modification
Any grade Grade 3 Grade 4 Any grade Grade 3 Grade 4
Leukopenia 39 (92.9) 19 (45.2) 3 (7.1) 34 (81.0) 11 (26.2) 0
Neutropenia 39 (92.9) 19 (45.2) 15 (35.7) 35 (83.3) 18 (42.9) 8 (19.0)
Anemia 21 (50.0) 0 0 22 (52.4) 0 0
AST increased 21 (50.0) 1 (2.4) 0 22 (52.4) 2 (4.8) 0
Hypoalbuminemia 21 (50.0) 0 0 21 (50.0) 0 0
Fatigue 20 (47.6) 0 0 20 (47.6) 1 (2.4) 0
Peripheral sensory neuropathy 19 (45.2) 0 0 22 (52.4) 1 (2.4) 0
Alopecia 18 (42.9) 0 0 23 (54.8) 0 0
Malaise 17 (40.5) 0 0 19 (45.2) 0 0
ALT increased 15 (35.7) 1 (2.4) 0 12 (28.6) 2 (4.8) 0
Nausea 12 (28.6) 0 0 13 (31.0) 1 (2.4) 0
Dysgeusia 10 (23.8) 0 0 9 (21.4) 0 0
Peripheral motor neuropathy 8 (19.0) 0 0 8 (19.0) 1 (2.4) 0
Pain 7 (16.7) 1 (2.4) 0 9 (21.4) 2 (4.8) 0
Mucositis oral 6 (14.3) 1 (2.4) 0 11 (26.2) 0 0
Constipation 4 (9.5) 0 0 7 (16.7) 0 0
Thrombocytopenia 4 (9.5) 0 0 2 (4.8) 0 0
Febrile neutropenia 3 (7.1) 3 (7.1) 0 2 (4.8) 2 (4.8) 0
Blood bilirubin increased 0 0 0 2 (4.8) 0 0
Creatinine increased 0 0 0 1 (2.4) 0 0
Fig. 2  Frequency of grade 3/4 neutropenia and leukopenia dur-
ing treatment cycles in bi-weekly group. a Neutropenia; b leukope-
nia. White and black columns represent grades 3 and 4, respectively. 
Black arrow indicates the timing of the schedule modification based 
on the adverse events in the first cycle
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were small. Therefore, the findings should be interpreted 
with caution.
In conclusion, this phase II study involving patients with 
MBC demonstrated that bi-weekly administration of eribu-
lin in patients who were intolerant to the standard regimen 
of eribulin had antitumor activity comparable to the standard 
therapy. Since the risk of adverse events was reduced after 
switching to bi-weekly regimen in the patients who were not 
tolerant to the standard regimen of eribulin, bi-weekly admin-
istration of eribulin might be an alternative option for such 
patients. In addition, the bi-weekly schedule may contribute 
to the future exploration of combination therapy of eribulin 
with other cancer agents.
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